The American journal of pediatric hematology/oncology · 2001 · 35 citations · 39 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyNeuro-oncologyCancer ImmunotherapyChemotherapy ResistanceTherapeutic ResistanceCell Therapy Resistance MechanismsGlutathione RepletionGlutathione SystemMelphalan ConditioningMyc In NeuroblastomaNeuroblastoma BiologyRefractory NeuroblastomaTumor Resistance
BACKGROUND: Alkylator resistance contributes to treatment failure in high-risk neuroblastoma. Buthionine sulfoximine (BSO) can deplete glutathione and synergistically enhance in vitro sensitivity to the alkylating agent melphalan (L-PAM) for many neuroblastoma cell lines, but optimal use of this combination needs to be defined because clinical responses have been less frequent and not durable. PATIENTS AND METHODS: The authors established and characterized a neuroblastoma cell line (CHLA-171) from a patient who died of progressive disease after treatment with BSO and low-dose L-PAM. RESULTS: CHLA-171 lacks MYCN amplification, expresses PGP (P-glycoprotein) 9.5 RNA, and shows cell surface antigen expression (human leukocyte antigen class I weakly positive, but HSAN 1.2 (hybridoma, SAN 1.2) and anti-GD2 (anti-ganglioside GD2 antibody) strongly positive) characteristic of neuroblastoma cell lines. Twenty-four hours of BSO treatment (0-1,000 micromol/L) maximally depleted CHLA-171 glutathione to 36% of baseline. The cytotoxic response of CHLA-171 to BSO and L-PAM, alone and in combination, was measured by digital image microscopy (DIMSCAN) over a range of drug concentrations and compared with drug levels obtained in the patient during BSO/L-PAM therapy. As single agents, CHLA-171 was highly resistant to L-PAM (LD90 = 42 micromol/L; peak plasma concentration in the patient equals 3.9 micromol/L) and moderately resistant to BSO (LD90 = 509 micromol/L; steady-state concentration in the patient equals 397 micromol/L). Treatment with a 10:1 (BSO:L-PAM) fixed ratio combination synergistically overcame resistance (3-4 logs of cell kill, combination index <1) at clinically achievable levels of BSO (100-400 micromol/L) and levels of L-PAM (10-40 micromol/L) clinically achievable only with hematopoietic stem cell support. CONCLUSIONS: The in vitro results obtained for CHLA-171 suggest that BSO/L-PAM therapy may be optimally effective for drug-resistant neuroblastoma using myeloablative doses of L-PAM.
39
The Medical Journal of Australia · 1999 · 3.4K citations
Katherine K. Matthay, Judith G. Villablanca, Robert C. Seeger et al. · New England Journal of Medicine · 1999 · 1.9K citations · Full text
Medicine, Oncology, Pharmacology +7
The International Neuroblastoma Pathology Classification (the Shimada system)
Hiroyuki Shimada, Inge M. Ambros, Louis P. Dehner et al. · Cancer · 1999 · 1K citations